Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European...
Bristol-Myers Squibb Company (NYSE:BMY) announced that 14 abstracts on Orencia have been accepted for presentation...
Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk...
Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that results from an interim analysis...
Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 36th Annual Global Health Care...
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in...
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for...
Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous...
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized...
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen
Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results of a Phase III trial (CheckMate -067)...
Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to...
Lilly to Participate in Goldman Sachs Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 36th Annual Global Healthcare...
Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced that they have...
Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First...
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from an interim analysis of CA209-040, a Phase...
